Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade

BACKGROUND: Development of novel agents targeting the androgen axis has led to improved overall survival in castration-resistant prostate cancer (CRPC). This study aimed to investigate the optimal timing of treatment with one such agent, abiraterone acetate (AA), in Japanese patients. MATERIALS AND...

全面介紹

Na minha lista:
書目詳細資料
發表在:Prostate Int
Main Authors: Nagai, Takashi, Naiki, Taku, Iida, Keitaro, Etani, Toshiki, Ando, Ryosuke, Hamamoto, Shuzo, Sugiyama, Yosuke, Akita, Hidetoshi, Kubota, Hiroki, Hashimoto, Yoshihiro, Kawai, Noriyasu, Yasui, Takahiro
格式: Artigo
語言:Inglês
出版: Asian Pacific Prostate Society 2018
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5857185/
https://ncbi.nlm.nih.gov/pubmed/29556485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.prnil.2017.07.001
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍